DEFB118、IL-8在卵巢浆液性肿瘤中的表达及临床意义

发布时间：2018-07-03 15:42

  本文选题：IL-8 + DEFB　； 参考：《青岛大学》2017年硕士论文

【摘要】：目的在蛋白水平研究白细胞介素-8(IL-8)、防御素β-118(DEFB118)在卵巢浆液性肿瘤(浆液性囊腺瘤、交界性浆液性囊腺瘤、浆液性囊腺癌)组织中的表达差异。分析IL-8和DEFB118在卵巢浆液性囊腺癌组织中的表达与其临床病理特征(FIGO分期、组织学分级、有无淋巴结转移及腹膜转移)之间的关系,以及两种蛋白在癌组织中表达的相关性,来研究IL-8、DEFB-118在卵巢浆液性恶性肿瘤的发生、发展及防御方面的作用,为卵巢恶性肿瘤的发病机制、临床诊断、治疗靶点等提供理论依据,同时为卵巢恶性肿瘤的早期发现、诊断和治疗及进一步研究提供一个新的方向。方法本研究采用免疫组织化学法对IL-8、DEFB118分别在46例卵巢浆液性囊腺瘤、32例卵巢交界性浆液性囊腺瘤、60例卵巢浆液性囊腺癌组织中的表达情况进行检测,探讨IL-8和DEFB118的表达与卵巢浆液性囊腺癌组织中FIGO分期、组织学分级、有无淋巴结转移及腹膜转移之间的关系,同时分析IL-8与DEFB-118在卵巢浆液性囊腺癌中的表达相关性。结果1.IL-8在卵巢浆液性囊腺癌组中的阳性表达率为78.33%,在卵巢浆液性囊腺瘤组的阳性表达率为15.22%,在卵巢交界性浆液性囊腺瘤组的阳性表达率为46.88%,卵巢浆液性囊腺癌组的阳性表达率显著高于后两者,其结果具有统计学意义(P0.05),两两比较,结果具有统计学意义(P0.017)。在卵巢浆液性囊腺癌组中,DEFB118的阳性表达率为68.33%,在卵巢交界性浆液性囊腺瘤组为50.00%,均高于卵巢浆液性囊腺瘤组的21.74%,其结果也具有统计学意义(P0.05),但卵巢交界性浆液性囊腺瘤组和卵巢浆液性囊腺癌组的阳性表达率比较无统计学意义(P0.017)。2.在卵巢浆液性囊腺癌组中,IL-8在FIGO分期晚期(Ⅲ-Ⅳ期)、高级别癌、发生淋巴结转移及腹膜转移的肿瘤组织中高表达,而在FIGO分期早期(Ⅰ-Ⅱ期)、低级别癌、无淋巴结及腹膜转移的肿瘤组织中呈现低表达。同样,DEFB118在FIGO分期晚期(Ⅲ-Ⅳ期)、高级别癌、发生淋巴结转移及腹膜转移的肿瘤组织中的表达明显高于其在FIGO分期早期(Ⅰ-Ⅱ期)、低级别癌、无淋巴结及腹膜转移的卵巢浆液性囊腺癌组织中。3.Spearman相关分析显示:IL-8与DEFB118两者在卵巢浆液性囊腺癌组织中的表达呈正相关(r=0.338,P0.05)。结论在卵巢浆液性肿瘤组织中,IL-8以及DEFB118在卵巢浆液性囊腺癌和卵巢交界性浆液性囊腺瘤的表达均高于卵巢浆液性囊腺瘤,IL-8在卵巢浆液性囊腺癌中的表达也高于卵巢交界性浆液性囊腺瘤,且IL-8以及DEFB118与卵巢浆液性囊腺癌的临床病理特征有关,两者具有一定相关性。提示卵巢浆液性囊腺癌的发生、发展及侵袭转移可能与之有关。
[Abstract]:Objective to study the expression of interleukin-8 (IL-8) and defensin 尾 -118 (DEFB118) in ovarian serous tumors (serous cystadenoma, borderline serous cystadenoma and serous cystadenocarcinoma). To analyze the relationship between the expression of IL-8 and DEFB118 in ovarian serous cystadenocarcinoma and their clinicopathological features (Figo stage, histological grade, lymph node metastasis and peritoneal metastasis), and the correlation between the expression of IL-8 and DEFB118 in cancer tissues. To study the role of IL-8 DEFB-118 in the occurrence, development and defense of ovarian serous malignant tumors, and to provide theoretical basis for the pathogenesis, clinical diagnosis and therapeutic targets of ovarian malignant tumors, as well as for the early detection of ovarian malignant tumors. Diagnosis and treatment and further research provide a new direction. Methods the expression of IL-8 DEFB118 in 46 cases of ovarian serous cystadenoma and 32 cases of ovarian borderline serous cystadenoma was detected by immunohistochemistry in 60 cases of ovarian serous cystadenocarcinoma. To investigate the relationship between the expression of IL-8 and DEFB118 and Figo stage, histological grade, lymph node metastasis and peritoneal metastasis in ovarian serous cystadenocarcinoma, and to analyze the correlation between IL-8 and DEFB-118 expression in ovarian serous cystadenocarcinoma. The positive expression rate of IL-8 was 78.33 in ovarian serous cystadenocarcinoma, 15.22 in ovarian serous cystadenoma, 46.88 in borderline ovarian cystadenoma and 46.88 in ovarian serous cystadenocarcinoma. The positive expression rate was significantly higher than that of the latter two. The results were statistically significant (P0.05), pairwise comparison, the results were statistically significant (P0.017). The positive rate of DEFB118 was 68.33 in ovarian serous cystadenocarcinoma group and 50.00th in borderline serous cystadenoma group, which was higher than 21.74 in ovarian serous cystadenoma group. The results were also statistically significant (P0.05), but the ovarian borderline serous cystadenoma was also characterized by ovarian borderline serous cystadenoma. The positive expression rates of cystadenoma and ovarian serous cystadenocarcinoma were not statistically significant (P0.017) .2. In ovarian serous cystadenocarcinoma group, IL-8 was highly expressed in advanced Figo stage (鈪，

本文编号：2094146